Skip to main content
Clinical Trials/ACTRN12615000220561
ACTRN12615000220561
Not yet recruiting
Phase 2

A randomized controlled trial of the efficacy of intravenous tenecteplase versus alteplase within 4.5 hours of ischemic stroke onset in patients undergoing endovascular therapy, utilizing dual target vessel occlusion and penumbral mismatch imaging selection

euroscience Trials Australia0 sites64 target enrollmentMarch 9, 2015

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
euroscience Trials Australia
Enrollment
64
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 9, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
euroscience Trials Australia

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients presenting with acute ischemic stroke eligible using
  • standard criteria to receive IV thrombolysis within 4\.5 hours
  • of stroke onset
  • 2\. Patient is 18 years or older
  • 3\. Intra\-arterial clot retrieval treatment can commence (groin
  • puncture) within 6 hours of stroke onset.
  • Imaging inclusion criteria
  • Dual target:
  • 5\. Arterial occlusion on CT angiography of the internal carotid, middle cerebral (M1/M2 segments) or basilar artery
  • 6\. Mismatch (only applies to anterior circulation)\- Using CT perfusion with a Tmax \>6 second delay perfusion volume and CT\-rCBF ischemic core volume.

Exclusion Criteria

  • 1\. Intracranial hemorrhage (ICH) identified by CT
  • 2\. Rapidly improving symptoms at the discretion of the
  • investigator
  • 3\. Pre\-stroke mRS score of \>\=4 (indicating previous disability)
  • 4\. Hypodensity in \>1/3 MCA territory or equivalent proportion
  • of basilar artery territory on non\-contrast CT
  • 5\. Contra indication to imaging with contrast agents
  • 6\. Any terminal illness such that patient would not be expected
  • to survive more than 1 year
  • 7\. Any condition that, in the judgment of the investigator could

Outcomes

Primary Outcomes

Not specified

Similar Trials